Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
LPL encodes lipoprotein lipase, which is expressed in heart, muscle, and adipose tissue. Additionally we are shipping Lipoprotein Lipase Kits (55) and Lipoprotein Lipase Proteins (19) and many more products for this protein.
Showing 10 out of 137 products:
Cat (Feline) Monoclonal Lipoprotein Lipase Primary Antibody for ELISA, FACS - ABIN1042621
Peterson, Ayyobi, Ma, Henderson, Reina, Deeb, Santamarina-Fojo, Hayden, Brunzell: Structural and functional consequences of missense mutations in exon 5 of the lipoprotein lipase gene. in Journal of lipid research 2002
Show all 4 references for ABIN1042621
Human Monoclonal Lipoprotein Lipase Primary Antibody for ELISA, WB - ABIN969262
Berk, Johnson, Lee, Zhang, Boozer, Pi-Sunyer, Fried, Albu: Higher post-absorptive skeletal muscle LPL activity in African American vs. non-Hispanic White pre-menopausal women. in Obesity (Silver Spring, Md.) 2008
Show all 2 references for ABIN969262
Cow (Bovine) Monoclonal Lipoprotein Lipase Primary Antibody for EIA, Func - ABIN125994
Voyta, Via, Kinnunen, Sparrow, Gotto, Smith: Monoclonal antibodies against bovine milk lipoprotein lipase. Characterization of an antibody specific for the apolipoprotein C-II binding site. in The Journal of biological chemistry 1985
In this study, most of the LPL (show LCP1 Antibodies) gene variants were not significantly different in adolescents with normal and elevated triglceryide levels
The data suggest the importance of C-mannosylation for LPL (show LCP1 Antibodies) functions.
The single nucleotide polymorphisms in lipoprotein lipase, ApoA5 (show APOA5 Antibodies), and CETP (show CETP Antibodies) were associated with serum triglycerides and HDL (show HSD11B1 Antibodies)-cholesterol levels, but not with coronary artery disease in Pakistani population under study.
An LPL (show LCP1 Antibodies) structural model suggests that the LPL (show LCP1 Antibodies) S447X truncation exposes residues implicated in LPL (show LCP1 Antibodies) binding to lipoprotein binding uptake receptors, such as GPIHBP1 (show GPIHBP1 Antibodies).
results confirm that LPL (show LCP1 Antibodies) expression is a strong predictor of outcome in chronic lymphocytic leukemia, indicating a progressive course with poor survival
Reduced LPL (show LCP1 Antibodies) expression in placenta, limited increase in LPL (show LCP1 Antibodies) level in maternal plasma, and abnormal lipid profiles were found in patients with intrahepatic cholestasis of pregnancy.
The presence of rare damaging mutations in LPL (show LCP1 Antibodies) was significantly associated with higher triglyceride levels and presence of coronary artery disease.
Data show that polymorphisms of rs662799 and rs2266788 in APOA5 (show APOA5 Antibodies) gene, rs320 in LPL (show LCP1 Antibodies) gene and rs708272 in CETP (show CETP Antibodies) gene had significant association with the effect of the lipid-lowering therapy via atorvastatin on ischemic stroke patients.
NOTCH1 (show NOTCH1 Antibodies) mutations are tightly associated with LPL (show LCP1 Antibodies) gene expression. LPL (show LCP1 Antibodies) expression is independently associated with poor outcome in CLL and can be measured as a categorical variable.
Polymorphisms in the LPL (show LCP1 Antibodies) gene are associated with increased risk of acute non-biliary pancreatitis.
miR (show MYLIP Antibodies)-29b targets LPL and TDG (show TDG Antibodies) genes and regulates apoptosis and triglyceride production in mammary epithelial cells.
apoC-I (show APOC1 Antibodies) and apoC-III (show APOC3 Antibodies) inhibit lipolysis by displacing LPL from lipid emulsion particles. We also propose a role for these apolipoproteins in the irreversible inactivation of LPL by factors such as angptl4 (show ANGPTL4 Antibodies).
ANGPTL4 (show ANGPTL4 Antibodies) is more accurately described as a reversible, noncompetitive inhibitor of LPL.
Our findings confirmed that three novel SNPs we identified in the LPL gene can affect fatty acid composition and carcass traits. Therefore, selection for AA and GA genotypes should be recommended to genetically improve beef quality and flavor.
Single nucleotide polymorphisms of the LPL gene might be useful genetic markers for growth traits in the bovine reproduction and breeding.
Results describe the functional role of the secondary structure in the lipoprotein lipase-binding portion of apolipoprotein CII (show APOC2 Antibodies).
regions that are responsive to activation by apoC-II (show APOC2 Antibodies)
domain (192-238) is absolutely necessary for apolipoprotein AV (show APOA5 Antibodies) in lipid binding and lipoprotein lipase activation
This study shows that TNF-alpha (show TNF Antibodies), by a Foxo1 (show FOXO1 Antibodies) dependent pathway, increases the transcription of ANGPTL4 (show ANGPTL4 Antibodies) which is secreted by the cells and causes inactivation of LPL.
Our findings suggest that neuronal LPL is involved in the regulation of body weight and composition in response to either the change in quantity (HF feeding) or quality (n-3 PUFA-enriched) of dietary fat
An LPL structural model suggests that the LPL S447X truncation exposes residues implicated in LPL binding to lipoprotein binding uptake receptors, such as GPIHBP1 (show GPIHBP1 Antibodies).
feeding induces lipasin, activating the lipasin-Angptl3 (show ANGPTL3 Antibodies) pathway, which inhibits LPL in cardiac and skeletal muscles to direct circulating TAG to WAT for storage
MiR (show MLXIP Antibodies)-590 agomir down-regulates LPL mRNA and protein expression in a mouse model of atherosclerosis.
Deficiency of Lipoprotein Lipase in Neurons Decreases AMPA (show GRIA3 Antibodies) Receptor Phosphorylation and Leads to Neurobehavioral Abnormalities in Mice
Systemic LPL deletion results in impaired glucose tolerance, whole-body and tissue-specific insulin (show INS Antibodies) resistance, which is associated with tissue lipid deposition in various insulin (show INS Antibodies) target tissues
Results indicated that aggregation of alpha-syn and reduction of UCHL1 (show UCHL1 Antibodies) expression in LPL-deficient mice may affect synaptic function.
the amount of LPL expressed in muscle and heart governed both the binding of chylomicron particles and the assimilation of chylomicron lipids in the tissue.
Maternal overnutrition induces LPL expression in trophoblasts by reducing the inhibitory effect of SIRT1 (show SIRT1 Antibodies) on PPARgamma (show PPARG Antibodies).
LPL encodes lipoprotein lipase, which is expressed in heart, muscle, and adipose tissue. LPL functions as a homodimer, and has the dual functions of triglyceride hydrolase and ligand/bridging factor for receptor-mediated lipoprotein uptake. Severe mutations that cause LPL deficiency result in type I hyperlipoproteinemia, while less extreme mutations in LPL are linked to many disorders of lipoprotein metabolism.
, O 1-4-5
, adipose lipoprotein lipase
, triacylglycerol lipase